The clinical and demographic characteristics of the SpACE Capsule Study patients. Values are n (%) unless otherwise specified.
| Characteristics | Values, n = 64 |
|---|---|
| Age, yrs, mean ± SD | 42 ± 13 |
| Sex | |
| Male | 30 (46.9) |
| Female | 34 (53.1) |
| Spondyloarthritis classification# | |
| Axial SpA (including AS) | 50 (78.1) |
| Peripheral SpA | 14 (21.9) |
| HLA-B27–positive | 38/49 (77.6) |
| Presence of GI symptoms | 36 (56.3) |
| Treatment | |
| NSAID* | 38 (59.4) |
| Etanercept | 7 (10.9) |
↵# SpA classification according to the ASAS clinical criteria24.
↵* NSAID stopped at least 4 weeks before capsule endoscopy. AS: ankylosing spondylitis; ASAS: Assessment of Spondyloarthritis international Society; NSAID: nonsteroidal antiinflammatory drugs; SpA: spondyloarthritis; GI: gastrointestinal.